A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT01013818 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to slow accrual

Conditions

Lymphoid Malignancies

Interventions

DRUG: HGS1029

Sponsor

Human Genome Sciences Inc.